Correction: The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression
Cureus
.
2023 Feb 13;15(2):c101.
doi: 10.7759/cureus.c101.
eCollection 2023 Feb.
Authors
Marcos Pantarotto
1
,
Rita Barata
2
,
Ricardo Coelho
2
,
Virginia Sousa
3
,
Catarina Carvalheiro
2
,
Ines Rolim
2
,
Patricia Garrido
2
,
Nuno GIl
2
,
Filipa Duarte-Ramos
4
,
Fernanda S Tonin
5
Affiliations
1
Oncology, Champalimaud Foundation, Lisbon, PRT.
2
Lung Unit, Champalimaud Foundation, Lisbon, PRT.
3
Dermatology, Champalimaud Foundation, Lisbon, PRT.
4
Faculty of Pharmacy, University of Lisbon, Lisbon, PRT.
5
Health & Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PRT.
PMID:
36819952
PMCID:
PMC9927028
DOI:
10.7759/cureus.c101
Abstract
[This corrects the article DOI: 10.7759/cureus.26729.].
Copyright © 2023, Pantarotto et al.
Publication types
Published Erratum